Previous Article | Next Article ![]()
Journal of Clinical Microbiology, 02 1995, 352-355, Vol 33, No. 2
M Di Stefano, F Sabri, T Leitner, B Svennerholm, L Hagberg, G Norkrans and F Chiodi
Human immunodeficiency virus type 1 (HIV-1) isolates obtained from the
blood of patients undergoing treatment with 3'-azido-3'-deoxythymidine
(zidovudine [AZT]) show a decreased sensitivity to the drug in vitro. The
aim of the present study was to determine if HIV-1 variants resistant to
AZT are present also in the brain compartment. We selected sequential HIV-1
isolates from the blood and the cerebrospinal fluid (CSF) of six patients
with HIV-1 infection undergoing AZT therapy for a time varying between 1
and 3 years. The isolates were used to infect peripheral blood mononuclear
cell cultures which were used to prepare viral DNA. The viral DNA was
amplified by PCR and then directly sequenced. Analysis of the reverse
transcriptase (RT) sequence of the isolates from the CSF during therapy
demonstrated that CSF-resistant isolates are characterized by the same
mutations documented in resistant isolates from the blood compartment.
Isolates obtained from one patient (patient 3) showed the same two
mutations (codons 70 and 215) in blood and CSF, whereas isolates obtained
from an additional four patients presented a different pattern of mutations
in the two compartments. We also analyzed the degree of amino acid homology
between RT sequences from blood and CSF isolates in patients before and
during AZT treatment. The percentages of amino acid variations were
approximately equal when isolates from the same or different compartments
were considered. Excluding the codons involved in AZT resistance, the time
point of sampling did not affect RT variations during therapy
significantly.(ABSTRACT TRUNCATED AT 250 WORDS)
Copyright © 1995 by the American Society for Microbiology. All rights reserved.
Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment
Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|